Aug 6, 2026 · 27 min · 11 segments
What do PMSF's relationships with pharmaceutical companies and other industry companies really mean for families? In this episode, Dr. Lauren Schmitt, Chief Science Officer, and Amanda Bergen…
Amanda BergenGuest
Lauren SchmittHost
This is going to be Jaguar gene therapy, PYC therapeutics, and neuron pharmaceuticals.
These are probably the ones that we come up the most, we're more frequently posting about, but these are not the only relationships with industry we have.
There's companies like Worldwide Clinical Trials that is more of this liaison that helps run those clinical trials for some of those groups.
And then we have a lot of companies that are more active in the DEE or developmental encephaly area that are working on drugs for seizures.
And I think something that you just said that I think is so important is there's, you know, a lot of different interest in Phelan-McDermid syndrome.
And we know that, you know, our population, those that have Phelan-McDermid syndrome is very diverse.
And so I think that it's important to note that there are many different symptoms.
It's sometimes looking at those different aspects and there's, you know, very specific companies or interest in
And I know we'll get into this a little bit later, but I mean, that's a lot of, you know, my role as chief science officer is to really, you know, help foster these partnerships or relationships we have.
but also seek out some new ones, find out some other groups that are doing research in specific symptoms potentially that overlap with Phelan-McDermid or even overlapping mechanisms of action that might be relevant.
Kind of on the flip side, why is it important for PMSF to have this relationship with industry?
This is going to be Jaguar gene therapy, PYC therapeutics, and neuron pharmaceuticals.
These are probably the ones that we come up the most, we're more frequently posting about, but these are not the only relationships with industry we have.
There's companies like Worldwide Clinical Trials that is more of this liaison that helps run those clinical trials for some of those groups.
And then we have a lot of companies that are more active in the DEE or developmental encephaly area that are working on drugs for seizures.
And I think something that you just said that I think is so important is there's, you know, a lot of different interest in Phelan-McDermid syndrome.
And we know that, you know, our population, those that have Phelan-McDermid syndrome is very diverse.
And so I think that it's important to note that there are many different symptoms.
It's sometimes looking at those different aspects and there's, you know, very specific companies or interest in
And I know we'll get into this a little bit later, but I mean, that's a lot of, you know, my role as chief science officer is to really, you know, help foster these partnerships or relationships we have.
but also seek out some new ones, find out some other groups that are doing research in specific symptoms potentially that overlap with Phelan-McDermid or even overlapping mechanisms of action that might be relevant.
Kind of on the flip side, why is it important for PMSF to have this relationship with industry?
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
